Aadi Bioscience Hits New 52-Week High of $4.48, Up 131.61%

Aadi Bioscience, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.48 on March 10, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 131.61%, significantly outpacing the S&P 500's performance of 20.78% during the same period. The company's market capitalization stands at USD 144 million, reflecting its position within the microcap category. Despite its recent stock performance, Aadi Bioscience remains in a loss-making position, as indicated by its P/E ratio, which is not applicable. The company has a price-to-book ratio of 0.91, suggesting that its stock may be undervalued relative to its book value. With a debt-to-equity ratio of -1.03 and a return on equity of -9.94%, Aadi Bioscience's financial metrics indicate a challenging landscape. The stock's previous 52-week low was recorded at USD 1.39, highlighting the significant upward movement it has experienced recently.